Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents

Inclusion Criteria: * Diagnosis of anemia of chronic kidney disease (CKD) * Diagnosis of non-dialysis-dependent (NDD) CKD with an estimated glomerular filtration rate of greater than (\>) 10 and less than (\<) 60 milliliters/minute/1.73 meters\^2 (mL/min/1.73 m\^2 ) or diagnosis of dialysis dependent (DD) CKD * Mean screening hemoglobin (Hb) \<10.0 grams/deciliters (g/dL) * Transferrin Saturation ≥ 20% Exclusion Criteria: * Anemia due to a cause other than CKD * Active bleeding or recent clinically significant blood loss * Treatment with an erythropoiesis-stimulating agents (ESA) within 8 weeks prior to Screening * History of sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia * Red Blood Cells transfusion within 4 weeks * Serum albumin level \<2.5 g/dL * Uncontrolled hypertension * Active malignancy or treatment for malignancy within the past 2 years prior to Screening * Evidence of iron overload or diagnosis of hemochromatosis * Known hypersensitivity to vadadustat or any excipients in vadadustat tablet